A5082283107- Pancreatic and Hepatic Oncology Research
- Radiomics and Machine Learning in Medical Imaging
- Ovarian cancer diagnosis and treatment
- Endometrial and Cervical Cancer Treatments
- Neuroendocrine Tumor Research Advances
- MRI in cancer diagnosis
- Lung Cancer Research Studies
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Renal cell carcinoma treatment
- Cancer Genomics and Diagnostics
- Neuroblastoma Research and Treatments
- Gallbladder and Bile Duct Disorders
- Hepatocellular Carcinoma Treatment and Prognosis
- Radiation Dose and Imaging
- Medical Imaging Techniques and Applications
- Uterine Myomas and Treatments
- Advanced X-ray and CT Imaging
- Pancreatitis Pathology and Treatment
- Cancer Immunotherapy and Biomarkers
- Intraperitoneal and Appendiceal Malignancies
- Gastric Cancer Management and Outcomes
- Cervical Cancer and HPV Research
- Cancer, Hypoxia, and Metabolism
- Gastrointestinal disorders and treatments
- Prostate Cancer Diagnosis and Treatment
The University of Texas MD Anderson Cancer Center
2016-2025
University of New Hampshire at Manchester
2024
Tufts University
2024
University of New Hampshire
2024
Post University
2024
Florida College
2021-2023
University of Florida
2022-2023
United States Department of the Treasury
2022
University of Houston
2022
The University of Texas Health Science Center at Houston
2021-2022
Abstract BACKGROUND: Experience with preoperative therapy for other cancers has led to an assumption that borderline resectable pancreatic can be converted therapy. In this study, the authors sought determine rate at which neoadjuvant is associated a reduction in size or stage of tumors. METHODS: Patients who had cancer and received before potentially undergoing surgery authors' institution between 2005 2010 were identified. The patients' pretreatment post‐treatment protocol computed...
We conducted a phase II trial of preoperative gemcitabine and cisplatin chemotherapy in addition to chemoradiation (Gem-Cis-XRT) pancreaticoduodenectomy (PD) for patients with stage I/II pancreatic adenocarcinoma.Chemotherapy consisted (750 mg/m(2)) (30 given every 2 weeks four doses. Chemoradiation weekly infusions (400 combined radiation therapy Gy 10 fractions administered over weeks) delivered 5 days per week. Patients underwent restaging 4 6 after completion and, the absence disease...
Standard therapies for localized inoperable intrahepatic cholangiocarcinoma (IHCC) are ineffective. Advances in radiotherapy (RT) techniques and image guidance have enabled ablative doses to be delivered large liver tumors. This study evaluated the effects of RT dose escalation treatment IHCC.Seventy-nine consecutive patients with IHCC were identified treated definitive from 2002 2014. At diagnosis, median tumor size was 7.9 cm (range, 2.2 17 cm). Seventy (89%) received systemic chemotherapy...
The therapeutic resistance of pancreatic ductal adenocarcinoma (PDAC) is partly ascribed to ineffective delivery chemotherapy cancer cells. We hypothesized that physical properties at vascular, extracellular, and cellular scales influence response gemcitabine-based therapy.We developed a method measure mass transport during routine contrast-enhanced CT scans individual human PDAC tumors. Additionally, we evaluated gemcitabine infusion resection in 12 patients, measuring incorporation into...
Abstract Purpose: Pancreatic ductal adenocarcinoma (PDAC) is a heterogeneous disease with variable presentations and natural histories of disease. We hypothesized that different morphologic characteristics PDAC tumors on diagnostic computed tomography (CT) scans would reflect their underlying biology. Experimental Design: developed quantitative method to categorize the morphology pretherapy CT from multiple datasets patients resectable metastatic correlated these patterns clinical/pathologic...
Objective: We sought to identify potential radiologic and serologic markers of pancreatic tumor response therapy, using pathologic major (pMR) as the objective endpoint. Background: previously demonstrated that a pMR preoperative defined detection <5% viable cancer cells in surgical specimen on histopathological analysis, is an important prognostic factor for patients with ductal adenocarcinoma (PDAC). Methods: Pretreatment posttreatment computed tomography scans consecutive who received...
Treating patients undergoing chemotherapy who display findings of liver toxicity, requires a solid understanding these medications. It is important for any clinician to have an index suspicion toxicity and be able recognize it, even on imaging. Cancer has evolved, newer medications that target cell biology different pattern may differ from the more traditional cytotoxic agents. There are several hepatic conditions can result keen clinical as well radiographic recognition paramount....
Endometrial carcinoma (EC) is the most common gynecologic malignancy in United States. Prognosis depends on patient age, histological grade, depth of myometrial invasion and/or cervical invasion, and presence lymph node metastases. Although EC staged surgically according to International Federation Gynecology Obstetrics (FIGO) system, preoperative imaging can assist optimal treatment planning. Several techniques such as transvaginal ultrasonography (TVUS), computed tomography (CT), magnetic...